Actualités Invesco Variable Rate Preferred ETF - VRP | Actions American Stock Exchange

Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona...

CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline...

Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

Primary and secondary lung function endpoints met Results support twice-daily dosing LONDON and RALEIGH...

Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona...

Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona...

Verona Pharma Announces November 2020 Virtual Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona...

Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020

Initiated ENHANCE Phase 3 clinical trials in COPD Completed $200 million private placement Commenced a pilot...

Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update...

LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA...

Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020

LONDON and RALEIGH, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA...

Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

LONDON and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA...

Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference

LONDON and RALEIGH, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA...

Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2...

LONDON and RALEIGH, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Invesco Variable Rate Preferred ETF (VRP)

Votre Hub pour des idées et discussions en direct en temps réel

VRP Actualités

Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

Verona Pharma Announces November 2020 Virtual Investor Conference Participation

Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020

Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update...

Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020

Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference

Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2...

Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD

Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020

Verona Pharma Announces August 2020 Virtual Investor Conference Participation

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Invesco Variable Rate Preferred ETF (VRP) Actualités

Invesco Variable Rate Preferred ETF (VRP)

Votre Hub pour des idées et discussions en direct en temps réel

VRP Actualités

Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

Verona Pharma Announces November 2020 Virtual Investor Conference Participation

Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020

Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update...

Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020

Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference

Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2...

Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD

Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020

Verona Pharma Announces August 2020 Virtual Investor Conference Participation

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application